A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers ; volume:8 ; number:1 ; day:23 ; month:4 ; year:2024 ; pages:1-16 ; date:12.2024
npj precision oncology ; 8, Heft 1 (23.4.2024), 1-16, 12.2024
- Urheber
-
Zhou, Dan-dan
Zhai, Xiao-tian
Zhang, Lan-wen
Xie, Zi-hui
Wang, Ying
Zhen, Yong-su
Gao, Rui-juan
Miao, Qing-fang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00584-z
- URN
-
urn:nbn:de:101:1-2407090928524.401019995109
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhou, Dan-dan
- Zhai, Xiao-tian
- Zhang, Lan-wen
- Xie, Zi-hui
- Wang, Ying
- Zhen, Yong-su
- Gao, Rui-juan
- Miao, Qing-fang
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
The First FDA-Approved Antibody-Drug Conjugate
Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers